Follow-up of Patients with Resected Thoracic Malignancies

Thoracic Surgery Clinics

Volumn 22, Issue 1, 2012, Pages 123-131

  Claiborne, Paul M ^a   Fowler, Clara S ^b   Vaporciyan, Ara A ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Follow up; Guideline; Malignancy; Surgery; Thoracic

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ANASTOMOSIS STENOSIS; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CHONDROSARCOMA; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; COST EFFECTIVENESS ANALYSIS; DECORTICATION; DESMOID TUMOR; DISEASE FREE INTERVAL; DISEASE SURVEILLANCE; ESOPHAGUS CANCER; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURAL MESOTHELIOMA; META ANALYSIS (TOPIC); OSTEOSARCOMA; OVERALL SURVIVAL; PATIENT COUNSELING; PHYSICAL EXAMINATION; PLEURA MESOTHELIOMA; PLEURECTOMY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW; THORAX CANCER; THORAX RADIOGRAPHY; THORAX WALL TUMOR; THYMOMA; VOCATIONAL REHABILITATION;

FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; THORACIC NEOPLASMS; THORACIC SURGICAL PROCEDURES;

EID: 81855192701     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2011.08.011     Document Type: Review

References (33)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. Edelman M.J., Schuetz J. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection. Curr Treat Options Oncol 2002, 3(1):67-73.
3. McCrory D.C., Lewis S.Z., Heitzer J., et al. Methodology for lung cancer evidence review and guideline development: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(Suppl 3):23S-28S.
4. Rubins J., Unger M., Colice G. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 2007, 132(Suppl 3):355S-367S.
5. National Comprehensive Cancer Network NCCN Guidelines and Derivative Information Products: User Guide Available at:, Accessed July 29, 2011. http://www.nccn.org/professionals/transparency.asp.
6. Ettinger D.S., Akerley W., Borghaei H., et al. NCCN clinical practice guidelines in oncology (NCCN guidelines): non-small cell lung cancer Version 3. 2011. Available at:, Accessed March 28, 2011. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
7. Henschke C.I., McCauley D.I., Yankelevitz D.F., et al. Early lung cancer action project: a summary of the findings on baseline screening. Oncologist 2001, 6(2):147-152.
8. The diagnosis and treatment of lung cancer (update of NICE clinical guideline 24) 2011, National Collaborating Centre for Cancer, NICE Clinical Guideline, (CG121). p. 198. Available at:, Accessed November 6, 2011. http://guidance.nice.org.uk/CG121.
9. Scottish Intercollegiate Guidelines Network. Management of patients with lung cancer: a national clinical guideline 2005(80):66. Available at: Accessed March 28, 2011. http://www.sign.ac.uk/pdf/sign80.pdf.
10. The diagnosis and treatment of lung cancer 2005, National Collaborating Centre for Acute Care, NICE Clinical Guideline, (CG024). p. 107. Available at:, Accessed June 16, 2011. http://www.rcseng.ac.uk/publications/docs/lung_cancer.html.
11. Pavlidis N., Hansen H., Stahel R. ESMO clinical practice guidelines: development, implementation and dissemination. Ann Oncol 2010, 21(Suppl 5):v7-v8.
12. Crino L., Weder W., van Meerbeeck J., et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v103-v115.
13. Walsh G.L., O'Connor M., Willis K.M., et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. Ann Thorac Surg 1995, 60(6):1563-1570.
14. Virgo K.S., McKirgan L.W., Caputo M.C., et al. Post-treatment management options for patients with lung cancer. Ann Surg 1995, 222(6):700-710.
15. Younes R.N., Gross J.L., Deheinzelin D. Follow-up in lung cancer: how often and for what purpose?. Chest 1999, 115(6):1494-1499.
16. Westeel V., Choma D., Clement F., et al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 2000, 70(4):1185-1190.
17. Subotic D., Mandaric D., Radosavljevic G., et al. Relapse in resected lung cancer revisited: does intensified follow up really matter? A prospective study. World J Surg Oncol 2009, 7:87.
18. The National Lung Screening Trial Team Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365(5):395-409.
19. Ajani J.A., Barthei J.S., Bentrem D.J., et al. NCCN clinical practice guidelines in oncology (NCCN guidelines): esophageal and esophagogastric junction cancers (excluding the proximal 5cm of the stomach) Version 1. 2011. Available at:, Accessed March 28, 2011. http://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf.
20. Stahl M., Budach W., Meyer H.J., et al. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v46-v49.
21. Allum W.H., Griffin S.M., Watson A., et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2002, 50(Suppl V):1-23.
22. Marom E.M. Imaging thymoma. J Thorac Oncol 2010, 5(10 Suppl 4):S296-S303.
23. Ettinger D.S., Akerley W., Borghael H., et al. NCCN clinical practice guidelines in oncology (NCCN guidelines): thymomas and thymic carcinomas Version 1. 2011. Available at:, Accessed March 28, 2011. http://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf.
24. Oberg K., Hellman P., Kwekkeboom D., et al. Neuroendocrine bronchial and thymic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v220-v222.
25. El-Bawab H.Y., Abouzied M.M., Rafay M.A., et al. Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence. Interact Cardiovasc Thorac Surg 2010, 11(4):395-399.
26. Mineo T.C., Ambrogi V., Mineo D., et al. Long-term disease-free survival in patients with radically resected thymomas: relevance of cell-cycle protein expression. Cancer 2005, 104(10):2063-2071.
27. Biermann J.S., Adkins D.R., Benjamin R.S., et al. NCCN clinical practice guidelines in oncology (NCCN guidelines): bone cancer Available at:, Accessed April 24, 2011. http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf.
28. Mehren M.V., Benjamin R.S., Bui M.M., et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines): soft tissue sarcoma 2011, The National Comprehensive Cancer Network, Version 1. 2011. Available at:, Accessed March 28, 2011. http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
29. Roberts C., Daffner R., Weissman B., et al. ACR appropriateness criteria follow-up of malignant or aggressive musculoskeletal tumors 2008, American College of Radiology (ACR), Reston (VA).
30. Tsao A.S., Wistuba I., Roth J.A., et al. Malignant pleural mesothelioma. J Clin Oncol 2009, 27(12):2081-2090.
31. Price B., Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009, 39(7):576-588.
32. Stahel R.A., Weder W., Lievens Y., et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v126-v128.
33. Robinson B.W., Creaney J., Lake R., et al. Soluble mesothelin-related protein: a blood test for mesothelioma. Lung Cancer 2005, 49(Suppl 1):5109-5111.